DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Drug: arsenic trioxide
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00045565

Locations: 🇺🇸
New Approaches to Brain Tumor Therapy Consortium, Baltimore, Maryland, United States

Karenitecin in Treating Patients With Recurrent Malignant Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2008-07-24

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00014521

Locations: 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 5 locations

Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: B-cell Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: thalidomide
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT00006226

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Phase 3

Active, not recruiting

Conditions: Recurrent Neuroblastoma
Regional Neuroblastoma
Stage 4S Neuroblastoma
Stage 4 Neuroblastoma
Localized Resectable Neuroblastoma
Localized Unresectable Neuroblastoma

Interventions: Drug: Isotretinoin
Biological: Aldesleukin
Other: Laboratory Biomarker Analysis
Biological: Dinutuximab
Other: Pharmacological Study
Other: Quality-of-Life Assessment
Biological: Sargramostim

First Posted Date: 2003-01-27

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1449

Registration Number: NCT00026312

Locations: 🇺🇸
AdventHealth Orlando, Orlando, Florida, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 194 locations

Vaccine Therapy in Treating Patients With Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020358

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00052351

Locations: 🇺🇸
Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)
Kidney Cancer

Interventions: Biological: recombinant interferon alfa
Biological: recombinant interleukin-12

First Posted Date: 2003-01-27

Last Posted Date: 2013-03-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00004244

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Phase 1

Completed

Conditions: Blastic Phase Chronic Myelogenous Leukemia
Relapsing Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions: Drug: imatinib mesylate
Drug: cytarabine

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00015834

Locations: 🇺🇸
University of California at Los Angeles (UCLA ), Los Angeles, California, United States

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Phase 1

Withdrawn

Conditions: Lymphoma
Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-28

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00024115

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer

Phase 1

Completed

Conditions: Metastatic Cancer
Liver Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00030082

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy